Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei Ma has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multiparametric CMR evaluation of myocardial remodeling in dystrophinopathy

    by Wenting Luo, Jia Liu, Jie Wang, Yun Yuan, Jianxiu Lian, Wei Li, Shouyi Wei, Xiaofeng Qin, Wei Ma, Jianxing Qiu

    Background: Cardiac involvement in dystrophinopathy progresses from diffuse myocardial remodeling to overt systolic failure. Multiparametric cardiac magnetic resonance (CMR) offers simultaneous insights into myocardial mechanics and tissue characterization, yet the optimal diagnostic parameters for tracking disease severity remain to be fully characterized. Objective: To objectively evaluate the descriptive and discriminative performance of integrating strain and quantitative T1 mapping parameters for identifying myocardial fibrosis burden and stratifying systolic dysfunction in patients with dystrophinopathy. Materials and methods: This retrospective study analyzed 55 patients with genetically confirmed dystrophinopathy and 30 healthy controls who underwent CMR between January 2020 and December 2024. Patients were sequentially stratified by late gadolinium enhancement (LGE) status (Group A: LGE-negative, n = 16; Group B: LGE-positive, n = 39), and further sub-stratified by left ventricular ejection fraction (LVEF) (Group C: LVEF ≥ 50%, n = 23; Group D: LVEF < 50%, n = 16). Least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation was applied for non-zero feature selection, followed by the construction of multivariable Firth penalized logistic regression models. Model comparisons were made using the non-parametric DeLong test. Results: Compared with Group A, Group B exhibited significant differences in LVEF ( p < .001), mid-ventricular circumferential strain (CS_Mid, p < .001), and native T1 in segment 11 (T1map_seg11, mid-inferolateral, p = .004). In single-parameter ROC analysis, CS_Mid, LVEF, and T1map_seg11 exhibited an area under the curve (AUC) of 0.842 [95% confidence interval (CI): 0.735–0.949], 0.828 (95% CI: 0.714–0.942), and 0.715 (95% CI: 0.549–0.880), respectively. The combined model of CS_Mid and T1map_seg11 achieved the AUC of 0.888 (95% CI: 0.793–0.983). Compared Group C with Group D, CS_Global and T1map_seg5 models yielded AUCs of 0.921 (95% CI: 0.822–1.000) and 0.823 (95% CI: 0.694–0.953). The combined model (CS_Global + T1map_seg5) achieved the AUC of 0.951 (95% CI, 0.864–1.000, DeLong p = .567 vs T1map_seg5, DeLong p = .101 vs. T1map_seg5). Conclusions: In dystrophinopathy, multiparametric CMR enables structural and functional assessment of myocardial remodeling. Segmental native T1, particularly in the basal and mid-inferolateral segments, provides complementary information on regional myocardial tissue abnormalities. In contrast, CS accounts for most of the discrimination of disease severity. These findings suggest that the distinctive contribution of CMR may lie in regional myocardial tissue characterization rather than conventional functional assessment.

  • Open Access

    Coronary stenosis in Fabry disease with optical coherence tomography imaging presentation: a case report

    by Zesheng Peng, Bo Zheng, Yawen Zhao, Wei Zhang, Wei Ma

    Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder and also a rare cause of coronary stenosis. We present a case of coronary stenosis in a 39-year-old man with FD, including optical coherence tomography (OCT) imaging findings. Case summary: A 39-year-old man was admitted with unstable angina. He had been previously diagnosed with FD through α-galactosidase A enzyme activity testing and genetic analysis. Coronary angiography (CAG) revealed 90% stenosis in the proximal left anterior descending artery (pLAD). The pre-procedural CAG-based fractional flow reserve (caFFR) was 0.57, and the CAG-based index of microcirculatory resistance (caIMR) was 14.4. Drug-coated balloon angioplasty was performed, achieving post-procedural stenosis of 0%, with caFFR improving to 0.86 and caIMR decreasing to 9.4. He had no traditional atherosclerotic cardiovascular disease risk factors. Although CAG indicated 90% stenosis of the pLAD, OCT imaging did not demonstrate typical atherosclerotic or fibrocalcific plaques. However, based on the patient’s clinical features, OCT findings, and previous literature, we could not definitively determine the specific aetiology of the coronary stenosis (FD, coronary atherosclerosis, or both). During a 2-year follow-up, he remained angina-free. Discussion: Although OCT may aid in differentiating FD-related coronary involvement due to its high resolution and ability to detect FD-compatible changes, it cannot reliably determine whether the fibrous plaque morphology and loss of layered architecture are attributable to FD-related coronary pathology or premature atherosclerosis, representing a fundamental imaging limitation.

  • Open Access

    Heterogeneity and Detection Rate of Hypertrophic Cardiomyopathy Phenotype in China: A Multicenter Echocardiography Study

    by Beining Wang, Bei Wang, Hui Sun, Mengyun Zhu, Fengjuan Yao, Wen Lu, Shun Wang, Jun Wang, Yunqi Shi, Mingxing Xie, et al.

    Background: Contemporary data on the clinical detection rate and profile of phenotypical hypertrophic cardiomyopathy (HCM) in major Chinese healthcare settings are limited. This multicenter study aimed to determine the detection rate and echocardiographic features of the HCM phenotype in a large Chinese cohort. Methods: This cross-sectional study analyzed echocardiography databases from nine medical centers across China, including adult patients examined during 2023. HCM phenotype was defined as end-diastolic wall thickness ≥15 mm in the left ventricle. Patients with moderate to severe aortic stenosis were excluded. Subcategories included phenotypes of obstructive HCM and apical hypertrophy. Results: Among 655,383 examinations, 2610 patients met the criteria of the HCM phenotype, yielding a detection rate of 0.40% (≈1 in 250). The mean age was 60.2 years with male predominance (70.3%). Asymmetric septal hypertrophy was present in 53.3% of patients. The most commonly involved site with maximal wall thickness was the interventricular septum (57.6%), followed by the apex (20.9%) and the basal septum (17.7%). The overall intra-left ventricular obstruction rate was 16.2%; left ventricular outflow tract obstruction (LVOTO) accounted for 12.1%. LVOTO patients had greater septal thickness, smaller left ventricular diastolic dimensions, and more mitral regurgitation. Female sex was associated with a significantly higher LVOTO rate than males (18.2% vs. 9.6%, p < 0.001). Pure apical hypertrophy was identified in 4.5% of patients, with an increasing detection rate in older age groups. Conclusions: This large-scale, multicenter study confirms a high clinical detection rate for the HCM phenotype (≈1 in 250) in major Chinese centers. Substantial phenotypic heterogeneity across age and sex, coupled with the identification of key factors associated with LVOTO, highlights the need for sex- and age-specific diagnostic strategies and therapeutic planning in clinical practice.

  • Intracardiac Echocardiography for Procedural Guidance of Left Atrial Appendage Occlusion From Right Atrium: A Subgroup From a Multicenter Randomized Controlled Trial With Two Intracardiac Echocardiography Imaging Systems

    by Bijun Huang, Ziyong Hao, Yashu Kuang, Jian Wang, Huiming Chu, Zhongping Ning, Haiying Li, Wei Ma, Xiwen Zhang, Ben He, et al.

    Background: Intracardiac echocardiography (ICE)‐guided left atrial appendage occlusion (LAAO) from left atrium under local anesthesia showed potential advantages over transesophageal echocardiography (TOE). This study sought to demonstrate the intraprocedural efficiency and safety of LAAO with ICE guidance in right atrium. Methods: In a multicenter randomized controlled trial to assess whether the imaging quality of a novel DynaSight ICE system (SONOSEMI, Shenzhen, China) is noninferior to the SoundStar (Biosense Webster, USA), a sub‐group analysis was performed in patients who underwent LAAO under local anesthesia with ICE guidance in right atrium. Results: Thirty‐three of 66 in the DynaSight group and 30 of 67 in the SoundStar group were performed LAAO with ICE guidance in right atrium. There were no statistical differences between two groups in baseline characteristics including demographics, cardiovascular comorbidities, CHA2DS2‐VASc score, and HAS‐BLED score. Both ICE systems had similar clear image qualities according to multi‐plane assessments for home view, atrial septum and left atrium, and judgments for occluders including displaying location and resolution. There was comparable procedural successful rate for device implantation (100% in the DynaSight group vs. 96.67% in the SoundStar group, p = 0.4762) and occurrence of major peri‐procedural complications including tamponade, device embolism, death, major bleeding, and ischemic stroke/transient ischemic attack/systemic embolism (0 of 33 in the DynaSight group vs. 3 of 30 in the SoundStar group, p = 0.1022). Conclusions: The DynaSight ICE system has the same clear image quality as the SoundStar, which‐guided LAAO with the catheter in right atrium is intraprocedural effective and safe for device implantation.

  • Open Access

    Long‐Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER‐CN Study

    by Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’AN Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, et al.

    Background: Long‐term efficacy and safety of mavacamten in Chinese patients with obstructive hypertrophic cardiomyopathy are unknown. Methods: Patients who completed the 30‐week, double‐blind, placebo‐controlled treatment period in EXPLORER‐CN (A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM), with no active safety concerns, were eligible to enter the long‐term extension period to receive 48‐week mavacamten treatment. Patients previously on mavacamten continued mavacamten (dose at week 30; mavacamten–mavacamten group); patients previously on placebo received mavacamten (starting dose, 2.5 mg once daily; placebo–mavacamten group). Key efficacy end points included change from baseline in echocardiographic measures, New York Heart Association functional class, 23‐item Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. Analyses were descriptive; no between‐group hypothesis testing was performed. Results: Seventy‐nine patients (mean age, 51.6 years; 27.8% women) entered the long‐term extension period (mavacamten–mavacamten, n=54; placebo–mavacamten, n=25). In the mavacamten–mavacamten group, numerical improvements in Valsalva and resting left ventricular outflow tract peak gradients were maintained through week 78 (mean change from baseline, −73.0 mm Hg [95% CI, −86.4 to −59.5]; and −56.3 mm Hg [95% CI, −67.1 to −45.5], respectively). Numerical improvements were also observed for other echocardiographic parameters, New York Heart Association class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, and cardiac biomarkers through week 78. In the placebo–mavacamten group, numerical improvements with mavacamten in these parameters were noted from week 30 to week 78. Long‐term mavacamten treatment appeared well tolerated; left ventricular ejection fraction <50% was rare. Conclusions: In this exploratory long‐term extension study, 78‐week mavacamten treatment appeared well‐tolerated and was associated with numerical improvements from baseline in echocardiographic parameters, New York Heart Association class, patient‐reported health status, and cardiac biomarkers in Chinese patients with obstructive hypertrophic cardiomyopathy. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05174416.

  • Open Access

    Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy: Patient-Reported Health Status Analysis up to 78 Weeks in the EXPLORER-CN Study

    by Zhuang Tian, Xiaoyan Li, Liwen Li, Qing Zhang, Jian’AN Wang, Yunqi Shi, Daoquan Peng, Wei Ma, Ping Yang, Xiang Cheng, et al.

    Introduction Improvement of symptoms, physical function, and quality of life is one treatment goal for patients with obstructive hypertrophic cardiomyopathy (HCM). Mavacamten improved left-ventricular outflow tract gradients in Chinese patients with obstructive HCM in the EXPLORER-CN trial. We report here a detailed analysis of patient-reported health status per the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ-23) in Chinese patients after 78 weeks of mavacamten. Methods Patients who completed the double-blind, placebo-controlled (DBPC) period of EXPLORER-CN with no active safety concerns could enter a long-term extension (LTE) period to receive mavacamten for 48 weeks at either the 30-week dose (mavacamten-mavacamten group) or a once-daily starting dose of 2.5 mg (subsequently adjusted via pharmacodynamics-based dose titration: placebo-mavacamten group). Health status endpoints included KCCQ-23 clinical summary score (CSS), overall symptom score (OSS), total symptom score (TSS), physical limitations score, and quality-of-life scores through week 78. Week 78 endpoint analyses were descriptive. Results In the DBPC period, 54 patients received mavacamten and 27 received placebo; of these, 54 and 25, respectively, entered the LTE period. KCCQ-23 CSS, OSS, and TSS improved with mavacamten and worsened with placebo during the DBPC period (mean change baseline to week 30: 5.7, 6.4, and 8.1, respectively [mavacamten-mavacamten group] and – 5.4, – 4.3, and – 4.8, respectively [placebo-mavacamten group]). CSS, OSS, and TSS continued to improve in the mavacamten-mavacamten group during the LTE period (mean change baseline to week 78: 7.1, 8.2, and 10.0, respectively). Scores improved in the placebo-mavacamten group after switching to mavacamten (mean change week 30 to week 78: 7.3, 9.5, and 5.7, respectively). Similar improvements in KCCQ-23 physical limitations and quality-of-life scores with mavacamten were observed throughout both study periods. Conclusions Long-term mavacamten treatment for up to 78 weeks led to sustained improvements in patient-reported health status, supporting long-term treatment with mavacamten for Chinese patients with symptomatic obstructive HCM. Trial Registration ClinicalTrials.gov identifier NCT05174416.

  • “Comparative analysis of cardiac dysfunction in non-functioning adrenal adenomas, primary aldosteronism, and essential hypertension”

    by Lin Liu, Xianfang Li, Wei Ma, Fangfang Fan, Ying Yang, Lu Zhang, Tieci Yi, Junqing Zhang, Jingcui Guo, Ying Gao

  • Open Access

    Efficacy and Safety of a Generic Clevidipine in Hypertensive Urgencies and Non‐Fulminant Hypertensive Emergencies: A Phase III, Multicenter, Randomized, Double‐Blind, Positive Drug Parallel‐Controlled Study

    by Xiaoning Han, Wei Ma, Bo Wang, Xiang Gu, Guangjun Wang, Ling Lin, Qiufang Lian, Dongna Guo, Xiaoqun Wan, Jiaying Zhu, et al.

    Hypertensive crises require rapid blood pressure control to prevent stroke and myocardial injury. Despite Cleviprex's efficacy, its high cost limits accessibility in China. This Phase III, multicenter, randomized, double‐blind study evaluated the efficacy and safety of a generic clevidipine (China's first injectable generic clevidipine emulsion) versus the branded drug Cleviprex in managing hypertensive emergencies and urgencies among Chinese patients. A total of 377 patients of 33 medical centers from December 2021 to December 2022 were randomized, with 189 in the generic clevidipine group and 188 in the control. As a result, 95.6% of patients in the generic clevidipine group and 93.6% in the control achieved the target systolic blood pressure (SBP) reduction within 30 min (rate difference 0.020, 90% CI: −0.019 to 0.060). The mean area under the curve (AUC) of SBP outside the target range within the first hour was comparable between groups (329.8 ± 238.16 in generic clevidipine vs. 347.9 ± 302.79 in control). The median time to first achieve the target range within 30 min was 12.0 min in both groups. The proportion of patients successfully transitioning to oral therapy within 6 h was 93.4% in the generic clevidipine group and 93.6% in the control group. The incidence of drug‐related adverse events (AEs) was reported in 50 patients (27.3%) in the generic clevidipine group and in 48 (27.9%) in the control, with no unexpected safety signals. The generic clevidipine demonstrated comparable efficacy and safety to the branded drug, supporting its potential as an effective and accessible therapeutic alternative for acute hypertension management. Trial Registration : chinadrugtrials.org.cn identifier: ChiCTR20212877.

  • Open Access

    Higher systolic blood pressure difference in left not right upper limb is associated with all-cause mortality risk in a community-based population

    by Min Li, Fangfang Fan, Jia Jia, Jianping Li, Wei Ma, Yan Zhang

    This study investigated inter-arm systolic blood pressure difference (IASBPD) and mortality risks in 8628 Chinese community residents from an atherosclerosis cohort. IASBPD was calculated by subtracting the systolic blood pressure of the left arm from that of the right arm. Participants were categorized as |IASBPD| P = 0.013). While the association with cardiovascular mortality was not statistically significant in this subgroup, the trend paralleled that observed for all-cause mortality. In conclusion, an elevated IASBPD is significantly associated with all-cause and cardiovascular mortality risks, with higher IASBPD in the left arm showing a stronger link to all-cause mortality risk.